

ITL BioMedical's Latest New Product to Meet Customers Needs

ITL Health Group (ASX:ITD), is pleased to announce the launch of Segment Sampler, ITL BioMedical's latest innovative product to support laboratory blood sampling processes. The product has been designed in direct response to customer requests and has already received positive feedback.



Segment Sampler

Segment Sampler follows the recently announced launch of Transfer Cap Set, a product used in the laboratory blood culture testing process. ITL's laboratory product sales are predominantly through large business to business partners and distributors in the growing worldwide blood testing sector.

Segment Sampler facilitates a safe, efficient process for obtaining biological sample from a blood bag tubing segment while reducing laboratory technician potential exposure to biologic product. There are a variety of applications for this product including obtaining a sample for use with point of release tests such as bacterial screening performed prior to a unit of platelets being transfused to a patient. Other applications for this product include obtaining samples from cellular therapy products such as cord blood.

ITL has for many years invested in the creation and manufacture of leading edge medical devices for the healthcare industry and in the last financial year spent \$1.95m in research and development across the groups' product lines. ITL BioMedical has a pipeline of multiple additional new products scheduled to reach the market in the current financial year.

Craig Wilson, General Manager of ITL BioMedical commented "I am very excited about the Segment Sampler, our pre-launch customer feedback has been very positive as it fills a real need in the market as we strive to make labs safer and more productive".

ITL Health Group

ITL is an innovative global medical technology company made up of two divisions; ITL BioMedical and MyHealthTest. ITL holds an IP portfolio of more than 50 patents and sells into 55 countries.

ITL BioMedical creates and manufactures leading edge medical devices for the clinical, blood banking, and laboratory markets and is a growing provider of specialist ancillary products for the blood culture testing market.

MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.



Ranked 16th most Innovative Company by the
AFR Innovative Companies Awards

Australian Securities Exchange

Code: ITD

Ordinary Shares

89,778,074

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director

Trevor Doolan	Chief Financial Officer & Company Secretary
---------------	--

ITL Contact

Trevor Doolan	Company Secretary
Phone:	+61 3 8773 3050
Email:	info@itlhealthgroup.com
Address	Unit 1, 63 Wells Road Chelsea Heights, Victoria, 3196

www.itlhealthgroup.com

Media

Walbrook IR	Ben Knowles
Phone:	+61 426 277 760
Email:	ben.knowles@walbrookir.co.au

About ITL BioMedical and the Blood Industry

ITL BioMedical is a division of ITL Health Group that sets industry standards for the innovative design and production of biological sampling systems and healthcare devices for human and animal use. ITL BioMedical's patented medical devices focus on safety and process efficiency for health care professionals, blood donors and patients.

ITL BioMedical's innovative healthcare products are sold into numerous verticals within the blood industry including; Blood Culture Testing, Blood Banking, Blood Stream Infection, Blood Pressure Monitoring (Invasive), and Pathology and Laboratory.

Global sales of blood products reached \$33.5 billion in 2016 and are expected to grow at a five-year CAGR of 4.9% to \$42.6 billion in 2021⁽¹⁾. The Blood Culture Testing market alone was estimated to be worth US\$3.3b in 2016 and is forecast to grow to US\$4.8b by 2021⁽²⁾.

(1) www.bccresearch.com/market-research/healthcare/blood-plasma-products-markets-report-hlc201a.html

(2) www.marketsandmarkets.com/PressReleases/blood-culture-test.asp

For more information or inquiries, visit ITLBioMedical.com